Development of PARP inhibitors in oncology
- 21 November 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 18 (1) , 31-43
- https://doi.org/10.1517/13543780802525324
Abstract
(2009). Development of PARP inhibitors in oncology. Expert Opinion on Investigational Drugs: Vol. 18, No. 1, pp. 31-43. doi: 10.1517/13543780802525324Keywords
This publication has 57 references indexed in Scilit:
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorThe EMBO Journal, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Targeting DNA repair as a promising approach in cancer therapyEuropean Journal Of Cancer, 2007
- Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunctionExperimental Gerontology, 2007
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyAnnals of Oncology, 2007
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- The Hallmarks of CancerCell, 2000
- Identification of a RING protein that can interact in vivo with the BRCA1 gene productNature Genetics, 1996